/** blogpostTitle: "Molbio Q1 FY27: Test-kit led scale-up, but quarters stay lumpy" blogpostSlug: "molbio-q1" blogpostCoverImageUrl: null blogpostCoverImageDescription: "Ultra-realistic corporate finance scene showing a clean desk with a laptop displaying a dashboard of quarterly financial metrics and operational KPIs. The dashboard includes a bar chart for Total Income across three quarters (Q1 FY26, Q4 FY26, Q1 FY27), a line chart for EBITDA margin trending from negative to mid-20s, and two small tiles showing Truenat devices sold and Truenat test kits sold. In the background, a subtle world map graphic suggests 90+ countries presence, and a second panel shows capacity utilization gauges at about 42% for devices and 58% for test kits. No logos or text labels outside the charts, modern professional lighting, neutral tones." blogpostShortTitle: "Molbio Q1 FY27: Recurring kits drive" */

Molbio Q1 FY27: Test-kit led scale-up, but quarters stay lumpy

Molbio Diagnostics opened FY27 with a sharp jump in reported profitability, driven mainly by higher Truenat test-kit consumption and a catch-up of deferred exports. In Q1 FY27, the company reported Total Income of INR 411.5 crore, EBITDA of INR 103.7 crore (25.2% margin) and PAT of INR 52.7 crore (12.8% margin).

But management also set the context quickly: this is not a linear quarter-to-quarter business. Molbio’s core demand is tied to public health procurement cycles and export order timing, which can move revenue between quarters. A concrete example showed up this quarter itself. Export orders worth about INR 57 crore that were meant to be billed in Q4 FY26 were deferred due to the Gulf situation and were recognised in Q1 FY27.

That combination of a consumables-led model and uneven ordering is central to how investors should read the numbers.

Q1 FY27 performance: a rebound, with timing effects

On the headline numbers, the year-on-year swing is large. Q1 FY26 had Total Income of INR 100.5 crore, EBITDA loss of INR 14.5 crore and PAT loss of INR 23.9 crore. Q1 FY27, in contrast, delivered positive operating leverage as volumes improved.

Operationally, the quarter saw Truenat devices sold at 164 units, while Truenat test kits sold were 6.24 million units. The contrast between devices and consumables is important because it explains why device sales can look volatile without breaking the recurring revenue thesis. The installed base is what drives kit pull-through, and kit demand can keep growing even when device placements are lower in a given quarter.

Exports were also a meaningful contributor in the quarter. The press release disclosed that exports were 16.48% of revenue from operations in Q1 FY27, versus 6.03% in Q4 FY26. Management attributed part of this to the deferred export billing from the previous quarter.

Financial snapshot

Note: Total Income and EBITDA include other income, as per company disclosure.

The business model: recurring kits anchored by an installed base

Molbio positions Truenat as a portable, battery-operated real-time polymerase chain reaction (PCR) platform, designed for decentralised or near-patient testing. The platform includes devices (UnoDx, Duo, Quattro) and proprietary single-use consumables (test kits consisting of sample preparation and micro-PCR chips).

The installed base is the foundation of the revenue model. The company disclosed 12,500-plus Truenat devices installed across 90-plus countries, and 17.56 million test kits sold in FY26. In FY26, test kits contributed 73.98% of product revenue, reinforcing that the mix is already consumables-led.

In practice, this mix can create operating leverage. Once devices are placed, incremental test-kit volumes tend to carry better profitability. That said, because a large part of demand is through public health programs, the timing of tenders and dispatches can cause quarter-level noise even if the underlying installed base continues to expand.

Capacity headroom and capex: scaling without near-term expansion

A key operational point repeated in both the presentation and the call was capacity headroom. Molbio disclosed FY26 utilisation of 42.30% for devices and 58.25% for test kits, with installed manufacturing capacity of 5,400 devices per annum and 39 million test kits per annum.

This matters for two reasons.

First, it suggests that near-term growth can be driven by volumes without immediate large greenfield capacity additions. Second, it frames the use of IPO proceeds more as efficiency and capability building, rather than capacity firefighting.

Management stated that out of about INR 200 crore raised in the IPO, around INR 72 crore is planned for automation. Separately, the CEO said that net issue proceeds are being deployed for capex including automation and building an R&D facility in Bengaluru.

Beyond Truenat: Prognosys and OptraScan as portfolio extensions

Molbio has expanded into adjacent diagnostics infrastructure through two key subsidiaries.

Prognosys Medical Systems operates in radiology imaging devices, including portable solutions under the PRORAD brand. Management highlighted EU Medical Device Regulation certification and US Food and Drug Administration 510(k) clearances for certain PRORAD systems. In Q1 FY27, management disclosed that about INR 11 crore of revenue came from Prognosys. For FY26, Prognosys delivered about INR 154 crore revenue and around INR 12 crore of profit after tax, making it accretive in the prior year.

OptraScan, in contrast, is positioned as an early-stage growth bet in digital pathology. Management stated OptraScan received US FDA 510(k) clearance in July 2026, covering an end-to-end workflow. However, they also explicitly guided that OptraScan is not expected to be profitable in FY27, and cited an approximate INR 9 crore loss. The company expects meaningful contribution from FY28 to FY29 as commercialization scales.

What management is guiding for FY27

Despite the quarter-level lumpiness, management provided explicit full-year guidance on the call:

1. Topline growth of roughly 25% in FY27.
2. EBITDA margin of about 24% to 25% in FY27.

They also said device sales for the year are expected to be in the historical range of about 2,200 to 2,600 units.

The guidance is consistent with the broader narrative: grow through test-kit consumption on the installed base, use capacity headroom, and continue investing in international go-to-market and R&D.

Takeaways for investors

Molbio’s Q1 FY27 numbers show how quickly profitability can change when test-kit volumes rise and fixed costs are absorbed. At the same time, the company has been clear that quarterly prints will remain uneven because of public health procurement cycles and export timing.

The more durable signals in this update are structural: the consumables mix (test kits at about three-fourths of product revenue in FY26), the size of the installed base across 90-plus countries, and capacity utilisation that leaves room to scale without near-term capacity capex. The main near-term watch-outs remain order timing volatility, export disruptions like the Gulf deferral, and OptraScan losses while it ramps.

For FY27, the market will likely focus less on smooth quarter-on-quarter progression and more on whether the company delivers its stated full-year targets: roughly 25% revenue growth and 24% to 25% EBITDA margin, while sustaining the installed-base driven kit engine and building a broader portfolio beyond tuberculosis.